Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.71 Consensus PT from Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned a consensus rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is $85.71.

A number of equities research analysts have recently commented on the company. Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Friday.

Structure Therapeutics Trading Up 1.1 %

NASDAQ:GPCR opened at $39.74 on Friday. Structure Therapeutics has a 1-year low of $21.79 and a 1-year high of $75.02. The business’s 50-day moving average price is $39.32 and its two-hundred day moving average price is $46.50. The firm has a market capitalization of $1.85 billion and a price-to-earnings ratio of -47.88.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Friday, March 8th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. Sell-side analysts predict that Structure Therapeutics will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GPCR. Picton Mahoney Asset Management bought a new position in shares of Structure Therapeutics during the 3rd quarter worth approximately $116,000. Sectoral Asset Management Inc. bought a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $139,000. ADAR1 Capital Management LLC bought a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $163,000. Washington University bought a new position in shares of Structure Therapeutics during the 3rd quarter worth approximately $215,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Structure Therapeutics by 208.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock worth $177,000 after purchasing an additional 2,939 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.